Lite Strategy (LITS) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Lite Strategy (LITS) over the past year, losing 32.1% versus a loss of 51.2%. Over five years, SCYX leads with a -90.5% price change compared with -97.9% for LITS. SCYNEXIS is the larger company by market cap ($40.6 million vs $38.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LITS | SCYX |
|---|---|---|
| Share price | $1.27 | $4.08 |
| Market cap | $38.62M | $40.59M |
| 1-day change | +4.10% | -3.32% |
| YTD return | -7.58% | -16.53% |
| 1-year return | -51.20% | -32.11% |
| 5-year return | -97.90% | -90.53% |
| EPS (TTM) | $-2.06 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.97 | $9.12 |
| 52-week low | $0.69 | $3.53 |
| Distance from 52-week high | -57.24% | -55.26% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +790.44% |
| Average volume | 462.76K | 279.10K |
| Shares outstanding | 30.41M | 9.95M |
| Employees | 5 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed LITS by 19.1 percentage points over the past year.
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
LITS vs SCYX FAQ
Which is bigger, Lite Strategy or SCYNEXIS?
SCYNEXIS (SCYX) is larger, with a market capitalization of $40.59M compared with $38.62M for Lite Strategy (LITS).
Which stock has performed better over the past year, LITS or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -51.20% for LITS (price return, excluding dividends). Past performance does not predict future results.
Are Lite Strategy and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.